Longo Miriam, Scappaticcio Lorenzo, Bellastella Giuseppe, Pernice Vlenia, Cirillo Paolo, Maio Antonietta, Castaldo Filomena, Giugliano Dario, Esposito Katherine, Maiorino Maria Ida
Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples 80138, Italy.
Unit of Endocrinology and Metabolic Diseases, University of Campania "Luigi Vanvitelli", Naples 80138, Italy.
Diabetes Metab Syndr Obes. 2020 Mar 18;13:777-784. doi: 10.2147/DMSO.S238588. eCollection 2020.
Type 1 diabetes is associated with high risk of cardiovascular disease (CVD). Reduced levels of circulating progenitor cells (CPCs) and endothelial progenitor cells (EPCs) have been indicated as a risk factor for adverse cardiovascular outcomes and death in people at high cardiovascular risk. The aim of the present study was to evaluate the change in CPCs and EPCs levels in a population of young type 1 diabetic patients treated with intensive insulin regimen over a period of 2 years.
A total of 204 type 1 diabetic patients, of whom 84 treated with insulin pump (CSII) and 120 with multiple daily insulin injections (MDI), completed a 2-year follow-up. Clinical measurements, including the indices of glycemic control and glucose variability, were collected at baseline and after 2 years. Both CPC and EPC cell count were assessed by flow cytometry.
Mean age of participants was 24.5 years and mean diabetes duration was 13.6 years. After 2 years, we found a significant reduction of HbA1c (-0.3% versus baseline, P <0.001), associated with decrease in mean amplitude of glucose excursion (MAGE) (-0.5 mmol/L versus baseline, P<0.001), continuous overall net glycemic action (CONGA) (-0.2 mmol/L versus baseline, P=0.006), and blood glucose standard deviation (BGSD) (-0.2 mmol/L versus baseline, P<0.001). The number of all EPCs phenotypes, but not CPC cell count, significantly raised up in the entire population, with higher increase in CSII group. MAGE resulted as an independent predictor for increased levels of both CD34+ (P = 0.020) and CD34+KDR+ (P = 0.004) cell count in the whole population.
Over a 2-year follow-up, young type 1 diabetic patients showed an increase in circulating EPCs levels, which was higher in patients with CSII. Glucose variability resulted as an independent predictor of the raised levels of EPCs in this selected population.
1型糖尿病与心血管疾病(CVD)的高风险相关。循环祖细胞(CPC)和内皮祖细胞(EPC)水平降低已被指出是心血管高风险人群发生不良心血管结局和死亡的一个风险因素。本研究的目的是评估在接受强化胰岛素治疗方案的年轻1型糖尿病患者群体中,CPC和EPC水平在2年期间的变化。
共有204例1型糖尿病患者完成了2年的随访,其中84例使用胰岛素泵(CSII)治疗,120例使用多次皮下胰岛素注射(MDI)治疗。在基线和2年后收集临床测量数据,包括血糖控制指标和血糖变异性指标。通过流式细胞术评估CPC和EPC细胞计数。
参与者的平均年龄为24.5岁,平均糖尿病病程为13.6年。2年后,我们发现糖化血红蛋白(HbA1c)显著降低(较基线降低-0.3%,P<0.001),同时平均血糖波动幅度(MAGE)降低(较基线降低-0.5 mmol/L,P<0.001)、连续总体净血糖作用(CONGA)降低(较基线降低-0.2 mmol/L,P = 0.006)以及血糖标准差(BGSD)降低(较基线降低-0.2 mmol/L,P<0.001)。在整个群体中,所有EPC表型的细胞数量显著增加,但CPC细胞计数未增加,CSII组的增加幅度更高。MAGE是整个群体中CD34+细胞计数(P = 0.020)和CD34+KDR+细胞计数(P = 0.004)升高的独立预测因素。
在2年的随访中,年轻1型糖尿病患者的循环EPC水平升高,CSII治疗的患者升高幅度更高。血糖变异性是这一特定群体中EPC水平升高的独立预测因素。